



BEST AVAILABLE COPY

#5

Docket No. JAB-1626

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants Jean-Paul LacBampe et al/HC

JAN 11 2002

Serial No. 109/891,881 Art Unit: 1624

TECH CENTER 1600/2900

Filed 06/26/2001 Examiner: V. Balasubramanian

For NOVEL IL-5 INHIBITING 6-AZURACIL DERIVATIVES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

December 5, 2001

(Date)

Ellen Ciambrone Coletti

Name of applicant, assignee, or Registered Representative

(Signature)

December 5, 2001

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Office Action mailed November 7, 2001. The pending claims are 1-7, and 10-14.

In the Office Action, restriction is required to one of the following.

BEST AVAILABLE COPY

Group I - Claims 1-7, 10 and 13-14, drawn to compound of Formula I, composition, process of making and method of use.

Group II - Claim 11, drawn to a process of marking a receptor using radiolabelled compound of Formula I.

Group III - Claim 12, drawn to a process of imaging an organ using radiolabelled compound of Formula I.

Applicants hereby elect the subject matter of Group I, that is, claims 1-7, 10 and 13-14.

Early favorable action on the merits is requested.

Respectfully submitted,



Ellen Ciambrone Coletti
Reg. No. 34,140
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359
December 5, 2001